Advanced Enzyme Technologies Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: April 24, 2025, 10:04 pm

Market Cap	3,329 Cr.
Current Price	298
High / Low	571/258
Stock P/E	23.4
Book Value	120
Dividend Yield	1.71 %
ROCE	15.2 %
ROE	11.2 %
Face Value	2.00
PEG Ratio	-12.58

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Advanced Enzyme Technologies Ltd

Competitors of Advanced Enzyme Technologies Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Lactose (India) Ltd	171 Cr.	121	247/84.3	24.7	36.5	0.00 %	18.0 %	15.5 %	10.0
MPS Pharmaa Ltd	5.73 Cr.	3.00	4.33/2.75		0.80	0.00 %	9.15 %	34.9 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	45.3 Cr.	61.0	94.9/44.5	15.4	11.9	0.00 %	9.72 %	3.44 %	10.0
Gujarat Inject (Kerala) Ltd	29.8 Cr.	20.4	29.0/13.1	30.4	6.64	0.00 %	2.65 %	2.08 %	10.0
Industry Average	18,419.34 Cr	1,141.94		44.86	183.39	0.32%	15.90%	16.58%	6.23

All Competitor Stocks of Advanced Enzyme Technologies Ltd

Quarterly Result

Metric	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Sales	127	134	132	121	139	142	139	147	158	161	158	155	146
Expenses	78	85	91	90	99	100	95	103	107	107	102	103	104
Operating Profit	49	49	40	31	40	42	44	44	51	54	55	51	42
OPM %	39%	37%	31%	26%	29%	29%	32%	30%	32%	33%	35%	33%	29%
Other Income	1	1	3	2	4	9	7	7	6	14	-6	7	10
Interest	0	0	1	1	1	1	1	1	1	1	1	1	1
Depreciation	9	9	9	9	9	9	8	9	9	9	9	9	9
Profit before tax	41	41	34	24	34	40	42	41	48	59	40	49	42
Tax %	27%	31%	26%	26%	23%	31%	24%	29%	27%	28%	25%	28%	21%
Net Profit	30	29	25	18	26	28	32	29	35	42	30	35	33
EPS in Rs	2.66	2.46	2.19	1.60	2.34	2.63	2.87	2.58	3.08	3.74	2.53	3.05	2.94

Last Updated: February 8, 2025, 11:37 am

Below is a detailed analysis of the quarterly data for Advanced Enzyme Technologies Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

For Sales, as of Sep 2024, the value is 146.00 Cr.. The value appears to be declining and may need further review. It has decreased from 155.00 Cr. (Jun 2024) to 146.00 Cr., marking a decrease of 9.00 Cr..
For Expenses, as of Sep 2024, the value is 104.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 103.00 Cr. (Jun 2024) to 104.00 Cr., marking an increase of 1.00 Cr..
For Operating Profit, as of Sep 2024, the value is 42.00 Cr.. The value appears to be declining and may need further review. It has decreased from 51.00 Cr. (Jun 2024) to 42.00 Cr., marking a decrease of 9.00 Cr..
For OPM %, as of Sep 2024, the value is 29.00%. The value appears to be declining and may need further review. It has decreased from 33.00% (Jun 2024) to 29.00%, marking a decrease of 4.00%.
For Other Income, as of Sep 2024, the value is 10.00 Cr.. The value appears strong and on an upward trend. It has increased from 7.00 Cr. (Jun 2024) to 10.00 Cr., marking an increase of 3.00 Cr..
For Interest, as of Sep 2024, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2024) which recorded 1.00 Cr..
For Depreciation, as of Sep 2024, the value is 9.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2024) which recorded 9.00 Cr..
For Profit before tax, as of Sep 2024, the value is 42.00 Cr.. The value appears to be declining and may need further review. It has decreased from 49.00 Cr. (Jun 2024) to 42.00 Cr., marking a decrease of 7.00 Cr..
For Tax %, as of Sep 2024, the value is 21.00%. The value appears to be improving (decreasing) as expected. It has decreased from 28.00% (Jun 2024) to 21.00%, marking a decrease of 7.00%.
For Net Profit, as of Sep 2024, the value is 33.00 Cr.. The value appears to be declining and may need further review. It has decreased from 35.00 Cr. (Jun 2024) to 33.00 Cr., marking a decrease of 2.00 Cr..
For EPS in Rs, as of Sep 2024, the value is 2.94. The value appears to be declining and may need further review. It has decreased from 3.05 (Jun 2024) to 2.94, marking a decrease of 0.11.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 7, 2025, 9:23 pm

Metric	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	219	239	222	293	329	391	420	444	502	529	541	624	628
Expenses	130	189	131	155	177	226	236	241	269	327	382	418	423
Operating Profit	90	50	91	138	152	165	184	203	233	203	158	206	204
OPM %	41%	21%	41%	47%	46%	42%	44%	46%	46%	38%	29%	33%	33%
Other Income	4	1	1	-3	3	1	5	6	9	6	21	21	19
Interest	10	13	9	8	4	9	5	4	3	3	3	4	4
Depreciation	8	10	9	9	13	18	21	26	29	35	35	35	36
Profit before tax	76	28	74	118	137	139	162	179	210	171	140	188	184
Tax %	34%	23%	31%	35%	32%	33%	28%	26%	28%	28%	26%	27%
Net Profit	50	21	51	77	93	94	116	133	151	124	104	137	137
EPS in Rs	4.52	1.85	4.60	6.97	8.20	8.07	9.95	11.58	13.06	10.70	9.45	11.92	11.89
Dividend Payout %	7%	6%	4%	3%	5%	6%	6%	5%	7%	9%	11%	43%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2013-2014	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	-58.00%	142.86%	50.98%	20.78%	1.08%	23.40%	14.66%	13.53%	-17.88%	-16.13%	31.73%
Change in YoY Net Profit Growth (%)	0.00%	200.86%	-91.88%	-30.20%	-19.70%	22.33%	-8.75%	-1.12%	-31.41%	1.75%	47.86%

Advanced Enzyme Technologies Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:	10%
5 Years:	8%
3 Years:	8%
TTM:	4%

Compounded Profit Growth
10 Years:	22%
5 Years:	5%
3 Years:	0%
TTM:	2%

Stock Price CAGR
10 Years:	%
5 Years:	16%
3 Years:	-2%
1 Year:	-25%

Return on Equity
10 Years:	15%
5 Years:	13%
3 Years:	11%
Last Year:	11%

Last Updated: Unknown

Balance Sheet

Last Updated: November 15, 2024, 1:46 am

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	22	22	22	22	22	22	22	22	22	22	22	22	22
Reserves	140	145	188	256	442	537	657	817	949	1,066	1,213	1,302	1,319
Borrowings	186	167	115	101	54	67	35	28	28	35	34	47	47
Other Liabilities	48	73	92	71	65	102	91	104	150	137	142	150	161
Total Liabilities	396	406	417	450	583	727	805	971	1,149	1,260	1,411	1,521	1,549
Fixed Assets	287	287	287	285	421	491	495	563	604	619	649	650	665
CWIP	2	2	5	7	8	11	10	10	10	15	22	41	34
Investments	0	0	0	0	0	0	111	124	121	102	360	403	396
Other Assets	107	117	125	158	153	226	188	275	414	524	380	427	454
Total Assets	396	406	417	450	583	727	805	971	1,149	1,260	1,411	1,521	1,549

Below is a detailed analysis of the balance sheet data for Advanced Enzyme Technologies Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

For Equity Capital, as of Sep 2024, the value is ₹22.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 22.00 Cr..
For Reserves, as of Sep 2024, the value is ₹1,319.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,302.00 Cr. (Mar 2024) to ₹1,319.00 Cr., marking an increase of 17.00 Cr..
For Borrowings, as of Sep 2024, the value is ₹47.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2024) which recorded 47.00 Cr..
For Other Liabilities, as of Sep 2024, the value is ₹161.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 150.00 Cr. (Mar 2024) to ₹161.00 Cr., marking an increase of 11.00 Cr..
For Total Liabilities, as of Sep 2024, the value is ₹1,549.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,521.00 Cr. (Mar 2024) to ₹1,549.00 Cr., marking an increase of 28.00 Cr..
For Fixed Assets, as of Sep 2024, the value is ₹665.00 Cr.. The value appears strong and on an upward trend. It has increased from 650.00 Cr. (Mar 2024) to ₹665.00 Cr., marking an increase of 15.00 Cr..
For CWIP, as of Sep 2024, the value is ₹34.00 Cr.. The value appears to be declining and may need further review. It has decreased from 41.00 Cr. (Mar 2024) to ₹34.00 Cr., marking a decrease of 7.00 Cr..
For Investments, as of Sep 2024, the value is ₹396.00 Cr.. The value appears to be declining and may need further review. It has decreased from 403.00 Cr. (Mar 2024) to ₹396.00 Cr., marking a decrease of 7.00 Cr..
For Other Assets, as of Sep 2024, the value is ₹454.00 Cr.. The value appears strong and on an upward trend. It has increased from 427.00 Cr. (Mar 2024) to ₹454.00 Cr., marking an increase of 27.00 Cr..
For Total Assets, as of Sep 2024, the value is ₹1,549.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,521.00 Cr. (Mar 2024) to ₹1,549.00 Cr., marking an increase of 28.00 Cr..

Notably, the Reserves (1,319.00 Cr.) exceed the Borrowings (47.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity +	41	43	54	93	107	116	129	141	163	122	140	141
Cash from Investing Activity +	-40	-25	-15	-10	-60	-60	-124	-43	-27	2	-286	-65
Cash from Financing Activity +	-3	-20	-36	-63	-65	-2	-43	-39	-26	-48	-26	-59
Net Cash Flow	-2	-1	2	21	-18	54	-38	60	109	75	-171	17

Free Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	-96.00	-117.00	-24.00	37.00	98.00	98.00	149.00	175.00	205.00	168.00	124.00	159.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	65	49	61	52	55	55	51	61	63	61	68	58
Inventory Days	318	387	403	358	352	339	363	361	346	402	343	375
Days Payable	121	81	89	68	57	78	46	43	56	60	67	40
Cash Conversion Cycle	262	356	374	342	351	315	369	379	353	404	344	393
Working Capital Days	95	5	-4	40	106	82	90	100	104	122	117	106
ROCE %	26%	12%	25%	36%	31%	25%	24%	22%	22%	15%	12%	15%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Promoters	52.70%	52.70%	49.88%	49.88%	49.88%	46.52%	45.92%	43.62%	43.50%	43.02%	42.95%	42.92%
FIIs	18.01%	18.72%	21.68%	21.74%	21.86%	21.89%	22.27%	22.54%	23.01%	12.03%	12.63%	12.57%
DIIs	6.90%	6.26%	5.60%	5.64%	5.73%	7.58%	6.49%	6.98%	7.56%	8.08%	8.02%	8.17%
Public	22.38%	22.32%	22.86%	22.76%	22.54%	24.02%	25.34%	26.88%	25.95%	36.87%	36.40%	36.31%
No. of Shareholders	86,573	84,376	84,277	81,183	77,537	75,052	72,642	73,034	68,640	65,222	66,758	67,351

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
HDFC Small Cap Fund - Regular Plan	3,979,689	0.58	130.55	3,979,689	2025-04-22 15:57:00	0%
ICICI Prudential ESG Fund	1,000,321	2.55	32.82	1,000,321	2025-04-22 15:57:00	0%
ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund	860,609	0.89	28.23	860,609	2025-04-22 15:57:00	0%
ICICI Prudential Value Discovery Fund	644,400	0.06	21.14	644,400	2025-04-22 17:25:43	0%
HDFC Multi Cap Fund	507,664	0.2	16.65	507,664	2025-04-22 15:57:00	0%
ICICI Prudential Equity & Debt Fund	115,918	0.02	3.8	115,918	2025-04-22 15:57:00	0%
Motilal Oswal S&P BSE Healthcare ETF	388	0.16	0.01	388	2025-04-22 17:25:43	0%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	2.00	2.00	2.00	2.00	2.00
Basic EPS (Rs.)	11.92	9.45	10.70	13.09	11.58
Diluted EPS (Rs.)	11.92	9.45	10.68	13.07	11.56
Cash EPS (Rs.)	15.40	12.42	14.20	16.10	14.22
Book Value[Excl.RevalReserv]/Share (Rs.)	122.61	114.84	102.00	92.25	77.67
Book Value[Incl.RevalReserv]/Share (Rs.)	122.61	114.84	102.00	92.25	77.67
Revenue From Operations / Share (Rs.)	55.79	48.35	47.35	44.92	39.76
PBDIT / Share (Rs.)	21.56	16.27	18.59	21.51	18.62
PBIT / Share (Rs.)	18.41	13.13	15.46	18.97	16.31
PBT / Share (Rs.)	16.80	12.55	15.30	18.83	16.04
Net Profit / Share (Rs.)	12.25	9.29	11.07	13.56	11.91
NP After MI And SOA / Share (Rs.)	11.92	9.45	10.70	13.08	11.58
PBDIT Margin (%)	38.64	33.64	39.26	47.89	46.84
PBIT Margin (%)	33.00	27.16	32.65	42.23	41.03
PBT Margin (%)	30.10	25.96	32.31	41.91	40.35
Net Profit Margin (%)	21.95	19.21	23.38	30.18	29.96
NP After MI And SOA Margin (%)	21.36	19.53	22.58	29.13	29.12
Return on Networth / Equity (%)	10.06	8.55	10.98	15.06	15.39
Return on Capital Employeed (%)	14.40	10.92	14.31	19.53	19.94
Return On Assets (%)	8.68	7.42	9.43	12.68	13.21
Long Term Debt / Equity (X)	0.01	0.01	0.01	0.01	0.00
Total Debt / Equity (X)	0.01	0.01	0.01	0.01	0.02
Asset Turnover Ratio (%)	0.42	0.33	0.32	0.38	0.40
Current Ratio (X)	7.61	9.31	10.00	7.64	5.85
Quick Ratio (X)	6.22	7.71	8.00	6.25	4.62
Inventory Turnover Ratio (X)	1.14	1.23	1.30	1.32	1.38
Dividend Payout Ratio (NP) (%)	41.94	10.58	8.41	4.58	5.18
Dividend Payout Ratio (CP) (%)	33.17	7.94	6.50	3.83	4.32
Earning Retention Ratio (%)	58.06	89.42	91.59	95.42	94.82
Cash Earning Retention Ratio (%)	66.83	92.06	93.50	96.17	95.68
Interest Coverage Ratio (X)	82.35	75.13	115.72	150.80	68.50
Interest Coverage Ratio (Post Tax) (X)	52.94	45.58	69.93	96.02	44.82
Enterprise Value (Cr.)	3814.49	2529.42	2942.98	3729.91	1560.37
EV / Net Operating Revenue (X)	6.11	4.68	5.56	7.43	3.51
EV / EBITDA (X)	15.82	13.91	14.16	15.52	7.50
MarketCap / Net Operating Revenue (X)	6.23	4.79	5.96	7.68	3.60
Retention Ratios (%)	58.05	89.41	91.58	95.41	94.81
Price / BV (X)	2.93	2.10	2.90	3.97	1.90
Price / Net Operating Revenue (X)	6.23	4.79	5.96	7.68	3.60
EarningsYield	0.03	0.04	0.03	0.03	0.08

After reviewing the key financial ratios for Advanced Enzyme Technologies Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 2.00.
For Basic EPS (Rs.), as of Mar 24, the value is 11.92. This value is within the healthy range. It has increased from 9.45 (Mar 23) to 11.92, marking an increase of 2.47.
For Diluted EPS (Rs.), as of Mar 24, the value is 11.92. This value is within the healthy range. It has increased from 9.45 (Mar 23) to 11.92, marking an increase of 2.47.
For Cash EPS (Rs.), as of Mar 24, the value is 15.40. This value is within the healthy range. It has increased from 12.42 (Mar 23) to 15.40, marking an increase of 2.98.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 122.61. It has increased from 114.84 (Mar 23) to 122.61, marking an increase of 7.77.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 122.61. It has increased from 114.84 (Mar 23) to 122.61, marking an increase of 7.77.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 55.79. It has increased from 48.35 (Mar 23) to 55.79, marking an increase of 7.44.
For PBDIT / Share (Rs.), as of Mar 24, the value is 21.56. This value is within the healthy range. It has increased from 16.27 (Mar 23) to 21.56, marking an increase of 5.29.
For PBIT / Share (Rs.), as of Mar 24, the value is 18.41. This value is within the healthy range. It has increased from 13.13 (Mar 23) to 18.41, marking an increase of 5.28.
For PBT / Share (Rs.), as of Mar 24, the value is 16.80. This value is within the healthy range. It has increased from 12.55 (Mar 23) to 16.80, marking an increase of 4.25.
For Net Profit / Share (Rs.), as of Mar 24, the value is 12.25. This value is within the healthy range. It has increased from 9.29 (Mar 23) to 12.25, marking an increase of 2.96.
For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 11.92. This value is within the healthy range. It has increased from 9.45 (Mar 23) to 11.92, marking an increase of 2.47.
For PBDIT Margin (%), as of Mar 24, the value is 38.64. This value is within the healthy range. It has increased from 33.64 (Mar 23) to 38.64, marking an increase of 5.00.
For PBIT Margin (%), as of Mar 24, the value is 33.00. This value exceeds the healthy maximum of 20. It has increased from 27.16 (Mar 23) to 33.00, marking an increase of 5.84.
For PBT Margin (%), as of Mar 24, the value is 30.10. This value is within the healthy range. It has increased from 25.96 (Mar 23) to 30.10, marking an increase of 4.14.
For Net Profit Margin (%), as of Mar 24, the value is 21.95. This value exceeds the healthy maximum of 10. It has increased from 19.21 (Mar 23) to 21.95, marking an increase of 2.74.
For NP After MI And SOA Margin (%), as of Mar 24, the value is 21.36. This value exceeds the healthy maximum of 20. It has increased from 19.53 (Mar 23) to 21.36, marking an increase of 1.83.
For Return on Networth / Equity (%), as of Mar 24, the value is 10.06. This value is below the healthy minimum of 15. It has increased from 8.55 (Mar 23) to 10.06, marking an increase of 1.51.
For Return on Capital Employeed (%), as of Mar 24, the value is 14.40. This value is within the healthy range. It has increased from 10.92 (Mar 23) to 14.40, marking an increase of 3.48.
For Return On Assets (%), as of Mar 24, the value is 8.68. This value is within the healthy range. It has increased from 7.42 (Mar 23) to 8.68, marking an increase of 1.26.
For Long Term Debt / Equity (X), as of Mar 24, the value is 0.01. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 23) which recorded 0.01.
For Total Debt / Equity (X), as of Mar 24, the value is 0.01. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 0.01.
For Asset Turnover Ratio (%), as of Mar 24, the value is 0.42. It has increased from 0.33 (Mar 23) to 0.42, marking an increase of 0.09.
For Current Ratio (X), as of Mar 24, the value is 7.61. This value exceeds the healthy maximum of 3. It has decreased from 9.31 (Mar 23) to 7.61, marking a decrease of 1.70.
For Quick Ratio (X), as of Mar 24, the value is 6.22. This value exceeds the healthy maximum of 2. It has decreased from 7.71 (Mar 23) to 6.22, marking a decrease of 1.49.
For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.14. This value is below the healthy minimum of 4. It has decreased from 1.23 (Mar 23) to 1.14, marking a decrease of 0.09.
For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 41.94. This value is within the healthy range. It has increased from 10.58 (Mar 23) to 41.94, marking an increase of 31.36.
For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 33.17. This value is within the healthy range. It has increased from 7.94 (Mar 23) to 33.17, marking an increase of 25.23.
For Earning Retention Ratio (%), as of Mar 24, the value is 58.06. This value is within the healthy range. It has decreased from 89.42 (Mar 23) to 58.06, marking a decrease of 31.36.
For Cash Earning Retention Ratio (%), as of Mar 24, the value is 66.83. This value is within the healthy range. It has decreased from 92.06 (Mar 23) to 66.83, marking a decrease of 25.23.
For Interest Coverage Ratio (X), as of Mar 24, the value is 82.35. This value is within the healthy range. It has increased from 75.13 (Mar 23) to 82.35, marking an increase of 7.22.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 52.94. This value is within the healthy range. It has increased from 45.58 (Mar 23) to 52.94, marking an increase of 7.36.
For Enterprise Value (Cr.), as of Mar 24, the value is 3,814.49. It has increased from 2,529.42 (Mar 23) to 3,814.49, marking an increase of 1,285.07.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 6.11. This value exceeds the healthy maximum of 3. It has increased from 4.68 (Mar 23) to 6.11, marking an increase of 1.43.
For EV / EBITDA (X), as of Mar 24, the value is 15.82. This value exceeds the healthy maximum of 15. It has increased from 13.91 (Mar 23) to 15.82, marking an increase of 1.91.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 6.23. This value exceeds the healthy maximum of 3. It has increased from 4.79 (Mar 23) to 6.23, marking an increase of 1.44.
For Retention Ratios (%), as of Mar 24, the value is 58.05. This value is within the healthy range. It has decreased from 89.41 (Mar 23) to 58.05, marking a decrease of 31.36.
For Price / BV (X), as of Mar 24, the value is 2.93. This value is within the healthy range. It has increased from 2.10 (Mar 23) to 2.93, marking an increase of 0.83.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 6.23. This value exceeds the healthy maximum of 3. It has increased from 4.79 (Mar 23) to 6.23, marking an increase of 1.44.
For EarningsYield, as of Mar 24, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.04 (Mar 23) to 0.03, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Advanced Enzyme Technologies Ltd as of April 25, 2025 is: 255.90

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of April 25, 2025, Advanced Enzyme Technologies Ltd is Overvalued by 14.13% compared to the current share price 298.00

Intrinsic Value of Advanced Enzyme Technologies Ltd as of April 25, 2025 is: 251.14

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of April 25, 2025, Advanced Enzyme Technologies Ltd is Overvalued by 15.72% compared to the current share price 298.00

Last 5 Year EPS CAGR: -1.86%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 22.08%, which is a positive sign. The company has higher reserves (694.69 cr) compared to borrowings (72.62 cr), indicating strong financial stability. The company has shown consistent growth in sales (413.92 cr) and profit (138.92 cr) over the years.	The stock has a high average Working Capital Days of 80.25, which may not be favorable. The stock has a high average Cash Conversion Cycle of 353.50, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Advanced Enzyme Technologies Ltd:
1. Net Profit Margin: 21.95%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 14.4% (Industry Average ROCE: 15.9%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 10.06% (Industry Average ROE: 16.58%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 52.94
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 6.22
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 23.4 (Industry average Stock P/E: 44.86)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.01
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Advanced Enzyme Technologies Ltd. is a Public Limited Listed company incorporated on 15/03/1989 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24200MH1989PLC051018 and registration number is 051018. Currently Company is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company's Total Operating Revenue is Rs. 365.47 Cr. and Equity Capital is Rs. 22.37 Cr. for the Year ended 31/03/2024.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	A - Wing, Sun Magnetica, 5th Floor, LIC Service Road, Thane Maharashtra 400604	info@advancedenzymes.com http://www.advancedenzymes.com

Management
Name	Position Held
Mr. Vasant Rathi	Non Executive Chairman
Mr. Mukund M Kabra	Whole Time Director
Ms. Rasika Rathi	Non Executive Director
Dr. Sunny Sharma	Non Executive Director
Mr. Pramod Kasat	Independent Director
Mrs. Vandana Tilak	Independent Director
Ms. Rajshree Patel	Independent Director
Mr. Nitin Desmukh	Independent Director
Mr. Vinodkumar Jajoo	Independent Director

FAQ

What is the intrinsic value of Advanced Enzyme Technologies Ltd?

Advanced Enzyme Technologies Ltd's intrinsic value (as of 25 April 2025) is ₹255.90 — 14.13% lower the current market price of 298.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 3,329 Cr. market cap, FY2025-2026 high/low of ₹571/258, reserves of 1,319 Cr, and liabilities of 1,549 Cr.

What is the Market Cap of Advanced Enzyme Technologies Ltd?

The Market Cap of Advanced Enzyme Technologies Ltd is 3,329 Cr..

What is the current Stock Price of Advanced Enzyme Technologies Ltd as on 25 April 2025?

The current stock price of Advanced Enzyme Technologies Ltd as on 25 April 2025 is 298.

What is the High / Low of Advanced Enzyme Technologies Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Advanced Enzyme Technologies Ltd stocks is ₹571/258.

What is the Stock P/E of Advanced Enzyme Technologies Ltd?

The Stock P/E of Advanced Enzyme Technologies Ltd is 23.4.

What is the Book Value of Advanced Enzyme Technologies Ltd?

The Book Value of Advanced Enzyme Technologies Ltd is 120.

What is the Dividend Yield of Advanced Enzyme Technologies Ltd?

The Dividend Yield of Advanced Enzyme Technologies Ltd is 1.71 %.

What is the ROCE of Advanced Enzyme Technologies Ltd?

The ROCE of Advanced Enzyme Technologies Ltd is 15.2 %.

What is the ROE of Advanced Enzyme Technologies Ltd?

The ROE of Advanced Enzyme Technologies Ltd is 11.2 %.

What is the Face Value of Advanced Enzyme Technologies Ltd?

The Face Value of Advanced Enzyme Technologies Ltd is 2.00.